Haut- und Lasercentrum Potsdam

Moderate to severe atopic dermatitis (M2S AD) is a chronic, relapsing inflammatory skin disease characterized by intense pruritus and eczematous lesions with significant impact on quality of life. Conventional therapies like cyclosporine are commonly prescribed drugs, along with tofacitinib as an off-label use. Recently, abrocitinib received approval for the management of M2S AD, a selective JAK1 inhibitor that has been well studied in the Western population. However, real-world comparative data among cyclosporine, tofacitinib, and abrocitinib remain limited. Therefore, we conducted a retrospective single-center study to assess the effectiveness and safety of cyclosporine, tofacitinib, and abrocitinib in adult patients with M2S AD over a 16-week treatment period. A single-center retrospective cohort study was conducted using electronic medical records of adult M2S AD patients treated with abrocitinib 100 mg once a day, tofacitinib 5 mg twice a day, or cyclosporine 100 mg once a day from April 2024 to March 2025. Clinical assessments were analyzed at baseline and weeks 4, 8, 12, and 16 using Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), and Dermatology Life Quality Index (DLQI). Serum IgE levels and adverse events (AEs) were also analyzed. Fifteen patients (five per group) were included as per the inclusion and exclusion criteria. At week 16, all three groups showed significant within-group improvements in EASI, SCORAD, DLQI, and Numerical Rating Scale (NRS) scores(p<0.001). However, compared with tofacitinib and cyclosporine, abrocitinib showed greater reduction in mean scores (EASI: 87% vs. 64% and 51%; SCORAD: 93% vs. 55% and40%; NRS: 85% vs. 62% and 51%; all p<0.01), respectively. DLQI also demonstrated a similar trend in abrocitinib (80%) against tofacitinib (59%) and cyclosporine (47%) (p<0.01). A significant decrease was also observed for serum IgE level in the abrocitinib group. In the abrocitinib group, two patients had headaches and nausea each, whereas two patients reported infection in the tofacitinib group. In the cyclosporine group, two patients had hypertension. All AEs were mild and resolved over the study period, with no treatment discontinuations. There was no statistical difference between any of the groups. In our small sample-sized analysis, all treatment groups were found to be efficacious and safe. However, abrocitinib showed a better clinical response than the other two groups in achieving symptom control. However, due to the small sample size, these claims can't be generalized, and further large-scale studies are needed to validate these findings and assess long-term outcomes.

Idelalisib in combination with rituximab is an efficacious treatment for patients suffering from chronic lymphocytic leukemia (CLL) with known limitations due to toxicities. However, the benefit after prior Bruton tyrosine kinase inhibitor (BTKi) therapy remains unclear. For this analysis, 81 patients included in a non-interventional registry study of the German CLL study group (registered at www.clinicaltrials.gov as # NCT02863692) meeting the predefined criteria of a confirmed diagnosis of CLL and being treated with idelalisib containing regimens outside clinical trials were considered. 11 patients were treatment naïve (13.6%) and 70 patients (86.4%) pretreated. Patients had median of one prior therapy line (range 0–11). Median treatment duration with idelalisib was 5.1 months (range 0–55.0 months). Of 58 patients with documented treatment outcome, 39 responded to idelalisib containing therapy (67.2%). Patients treated with the BTKi ibrutinib as last prior treatment prior to idelalisib responded in 71.4% compared to a response rate of 61.9% in patients without prior ibrutinib. Median event free survival (EFS) was 15.9 months with a 16 versus 14 months EFS in patients with ibrutinib as last prior treatment or not, respectively. Median overall survival was 46.6 months. In conclusion, treatment with idelalisib appears to have a valuable impact in patients being refractory to prior ibrutinib therapy even though there are limitations in our analysis due to the low number of patients included.

The high work-related loads on the skin of dancers is the result of numerous factors. While initial studies have looked at the consequences of exposure, information on skin condition is still completely lacking. This study includes for the first time an analysis of the skin as well as the relevant skin care behaviour. Methods: A total of n = 35 professional dancers (PT) underwent skin analysis (transepidermal water loss, TEWL; moisture content and oil level) as part of a dermatological examination. This was done at different work load periods (phase of increased demands and resting phases, T1 and T0, respectively). Results: Acne (17.1%), herpes labialis (8.6%), and allergic rhinitis (14.3%) were among the most common pre-existing conditions. Low moisture contents and oil levels of the skin were found in selected localizations. TEWL index values were normal. There were no significant differences in measured values between T0 and T1. Subjects with skin lesions at rest showered significantly more often than their unaffected counterparts. Inflammation was particularly frequent after hair removal, especially in the intimate area (40.6%). Conclusions: Occupational exposures appear to be reflected in the results. However, studies with larger groups are needed to verify these results.

Background:There is a growing interest in the application of hyaluronic acid (HA) derivatives in skin quality improvement. The aim of this study was to confirm safety and effectiveness of cohesive polydensified matrix-hyaluronic acid + glycerol (CPM-HA20G; Belotero Revive) in revitalization of early-onset photodamaged facial skin.Methods:A total of 159 subjects with early signs of facial photodamaged skin were randomized in a 2:1 ratio to multiple- or single-dose treatment with CPMHA20G. Effectiveness assessments included biophysical measurements of skin hydration; elasticity, firmness, and roughness; investigator- and subject-assessed Global Aesthetic Improvement Scales; and FACE-Q Skin Changes and Treatment Satisfaction questionnaires.Results:In both treatment groups, skin hydration improved from baseline to all follow-up visits in subjects with dry or very dry skin. This improvement was significant at week 16 after initial treatment in the multiple-dose group (P = 0.0013). Investigator- and subject-reported outcomes showed that the majority of subjects across all skin hydration types benefited from treatment, with higher satisfaction rates observed in the multiple-dose group. According to investigator-assessed Global Aesthetic Improvement Scale, 90.7% of subjects at week 12 in the multiple-dose and 74.6% of subjects at week 4 in the single-dose group were rated as at least “improved.” All related treatment-emergent adverse events were transient, expected injection-site reactions of mild to moderate intensity.Conclusions:Effectiveness of CPM-HA20G for skin hydration in subjects with dry or very dry skin was demonstrated up to 9 months after last injection. Overall, CPM-HA20G demonstrated effective and safe use in facial skin revitalization among subjects with early-onset photodamaged skin.

Facial aging is characterized by volume loss and progressive hollowing of temples and cheeks. Biodegradable filler materials are preferred over nonabsorbable materials; of these, hyaluronic acid (HA) fillers are the most often used because of their favorable effectiveness and safety profile. To confirm the safety and effectiveness of Cohesive Polydensified Matrix (CPM)-HA26 gel in the treatment of volume deficiency. Subjects received up to 2 treatments in the temples and/or cheeks. A blinded investigator assessed improvement according to the Merz Temple Volume Scale (MTVS) and Merz Cheek Fullness Assessment Scale (MCFAS). Subjects were followed for 48 weeks after the last treatment. In total, 87 healthy subjects were enrolled. The proportion of subjects achieving at least a 1-grade improvement on MTVS and/or MCFAS was above 70% for each (MTVS: Weeks 4, 24, and 48 = 95.4%, 94.2%, and 77.0%; MCFAS: Weeks 4, 24, and 48 = 92.3%, 83.1%, and 71.8%). Based on MTVS and MCFAS scores at Visit 5, improvement remained visible at up to 48 weeks. No treatment-related serious AEs occurred. CPM-HA26 demonstrated both a favorable safety and effectiveness profile, with improvement in facial volume evident for up to 48 weeks. It was well tolerated and had a positive, long-lasting effect.

JDDG: Journal der Deutschen Dermatologischen GesellschaftVolume 17, Issue 3 p. 336-339 Diagnosequiz Scharf begrenzte, leicht infiltrierte, erythematosquamöse Plaque mit fokaler Alopezie der Augenbraue Stephanie Gorbatsch, Corresponding Author Stephanie Gorbatsch info@durani-facharzt.de Haut- und Laserzentrum Heidelberg, Heidelberg, Deutschland Korrespondenzanschrift Dr. med. Stephanie Gorbatsch Haut- und Laserzentrum Heidelberg Bergheimer Straße 56a 69115 Heidelberg E-Mail: info@durani-facharzt.deSearch for more papers by this authorWolfgang Hartschuh, Wolfgang Hartschuh Haut- und Laserzentrum Heidelberg, Heidelberg, Deutschland Hautklinik, Universitätsklinikum Heidelberg, Heidelberg, DeutschlandSearch for more papers by this author Stephanie Gorbatsch, Corresponding Author Stephanie Gorbatsch info@durani-facharzt.de Haut- und Laserzentrum Heidelberg, Heidelberg, Deutschland Korrespondenzanschrift Dr. med. Stephanie Gorbatsch Haut- und Laserzentrum Heidelberg Bergheimer Straße 56a 69115 Heidelberg E-Mail: info@durani-facharzt.deSearch for more papers by this authorWolfgang Hartschuh, Wolfgang Hartschuh Haut- und Laserzentrum Heidelberg, Heidelberg, Deutschland Hautklinik, Universitätsklinikum Heidelberg, Heidelberg, DeutschlandSearch for more papers by this author First published: 28 March 2019 https://doi.org/10.1111/ddg.13760_gAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Volume17, Issue3March 2019Pages 336-339 RelatedInformation